Fluticasone furoate/vilanterol

Innoviva Reports Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Managed care, Pharmaceutical, Health, Medical devices, Ellipta, Finance, Financial economics, Fluticasone furoate/vilanterol, Money, Valuation, NASDAQ, Economy

Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company) today reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (Innoviva and the Company) today reported financial results for the second quarter ended June 30, 2021.
  • Increase in fair values of strategic equity and long-term investments of $45.3 million in the second quarter of 2021 was mainly due to higher net valuation, as of June 30, 2021.
  • RELVAR/BREO ELLIPTA global net sales increased meaningfully compared to the second quarter of 2020.
  • ANORO ELLIPTA global net sales increased by 7% in the second quarter of 2021.

Innoviva Announces Strategic Repurchase of GSK’s Equity Stake

Retrieved on: 
Thursday, May 20, 2021
Managed care, Pharmaceutical, Health, Medical devices, Drugs, Ellipta, Long-acting beta-adrenoceptor agonist, Beta2-adrenergic agonist, XC2, Fluticasone furoate/vilanterol

We believe that it materially accelerates the delivery of our strategy, while also meaningfully improving our shares\xe2\x80\x99 long-term trading dynamics with an aligned shareholder base.

Key Points: 
  • We believe that it materially accelerates the delivery of our strategy, while also meaningfully improving our shares\xe2\x80\x99 long-term trading dynamics with an aligned shareholder base.
  • Under the Long-Acting Beta2 Agonist (\xe2\x80\x9cLABA\xe2\x80\x9d) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR\xc2\xae/BREO\xc2\xae ELLIPTA\xc2\xae and ANORO\xc2\xae ELLIPTA\xc2\xae.
  • The words \xe2\x80\x9canticipate\xe2\x80\x9d, \xe2\x80\x9cexpect\xe2\x80\x9d, \xe2\x80\x9cgoal\xe2\x80\x9d, \xe2\x80\x9cintend\xe2\x80\x9d, \xe2\x80\x9cobjective\xe2\x80\x9d, \xe2\x80\x9copportunity\xe2\x80\x9d, \xe2\x80\x9cplan\xe2\x80\x9d, \xe2\x80\x9cpotential\xe2\x80\x9d, \xe2\x80\x9ctarget\xe2\x80\x9d and similar expressions are intended to identify such forward-looking statements.
  • No forward-looking statements can be guaranteed and actual results may differ materially from such statements.

Innoviva Reports Fourth Quarter 2020 Financial Results

Retrieved on: 
Wednesday, February 3, 2021
Biotechnology, Pharmaceutical, Health, Drugs, Combination drugs, Ellipta, Health care, Clinical medicine, Glucocorticoids, Fluticasone furoate/vilanterol, Fluticasone furoate/umeclidinium bromide/vilanterol

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2020.
  • Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: RELVAR/BREO ELLIPTA global net sales increased by 5%, ANORO ELLIPTA global net sales increased by 10%, and TRELEGY ELLIPTA global net sales increased by 42% in the fourth quarter of 2020, compared to the same quarter of 2019.
  • Fourth quarter 2020 net sales of RELVAR/BREO ELLIPTA by GSK were $372.8 million, up 5% from $354.4 million in the fourth quarter of 2019, with $141.0 million in net sales from the U.S. market and $231.8 million from non-U.S. markets.
  • Fourth quarter 2020 net sales of ANORO ELLIPTA by GSK were $200.9 million, up 10% from $182.7 million in the fourth quarter of 2019, with $119.4 million net sales from the U.S. market and $81.5 million from non-U.S. markets.

Innoviva Reports Third Quarter 2020 Financial Results

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Pharmaceutical, Health, Ellipta, Combination drugs, Fluticasone furoate/vilanterol, NASDAQ, Finance

Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020.
  • Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: RELVAR/BREO ELLIPTA global net sales increased by 38% compared to the third quarter of 2019.
  • ANORO ELLIPTA global net sales increased by 3% in the third quarter of 2020 compared to the same quarter of 2019.
  • With this additional investment, Innoviva owned approximately 52.6% of Entasis outstanding common stock as of September 30, 2020.

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

Retrieved on: 
Tuesday, October 13, 2020
Drugs, Clinical medicine, Health, Chronic lower respiratory diseases, Combination drugs, Muscarinic antagonists, Chronic obstructive pulmonary disease, Long-acting beta-adrenoceptor agonist, RPL-554, Phosphodiesterase, Fluticasone furoate/umeclidinium bromide/vilanterol, Fluticasone furoate/vilanterol

U.S. sales of medicines used for chronic maintenance therapy of COPD were $9.6 billion in 2019.

Key Points: 
  • U.S. sales of medicines used for chronic maintenance therapy of COPD were $9.6 billion in 2019.
  • About 1.2 million U.S. COPD patients on dual/triple inhaled therapy, long-acting beta-agonist (LABA)/long-acting muscarinic antagonist (LAMA) +/- inhaled corticosteroid (ICS) remain uncontrolled, experiencing symptoms that impair quality of life.
  • Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4).
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

Retrieved on: 
Wednesday, September 9, 2020
Health, FDA, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Health, Drugs, Respiratory therapy, Dosage forms, Combination drugs, Muscarinic antagonists, Asthma, Ellipta, Fluticasone furoate/umeclidinium bromide/vilanterol, Inhaler, Fluticasone furoate/vilanterol, Metered-dose inhaler, asthma, the CAPTAIN Study, Trelegy Ellipta (FF/UMEC/VI) in the US, GSK, Innoviva

The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US.

Key Points: 
  • The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US.
  • We welcome the news that for appropriate patients, Trelegy Ellipta will now be available as a new treatment option.
  • The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management.
  • Trelegy Ellipta was approved in the US on 9 September 2020 for the maintenance treatment of asthma in patients aged 18 years and older.

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

Retrieved on: 
Wednesday, September 9, 2020
Medical Supplies, Health, FDA, Medical devices, Clinical trials, Pharmaceutical, Biotechnology, Health, Drugs, Respiratory therapy, Dosage forms, Combination drugs, Muscarinic antagonists, Asthma, Ellipta, Fluticasone furoate/umeclidinium bromide/vilanterol, Inhaler, Fluticasone furoate/vilanterol, Metered-dose inhaler, asthma, the CAPTAIN Study, Trelegy Ellipta (FF/UMEC/VI) in the US, GSK, Innoviva

The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US.

Key Points: 
  • The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the US.
  • We welcome the news that for appropriate patients, Trelegy Ellipta will now be available as a new treatment option.
  • The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management.
  • Trelegy Ellipta was approved in the US on 9 September 2020 for the maintenance treatment of asthma in patients aged 18 years and older.

Innoviva Reports Second Quarter 2020 Financial Results

Retrieved on: 
Wednesday, July 29, 2020
Biotechnology, Finance, Health, Professional services, Pharmaceutical, Drugs, Combination drugs, Ellipta, Fluticasone furoate/vilanterol, Umeclidinium bromide/vilanterol, NASDAQ

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2020.

Key Points: 
  • Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2020.
  • ANORO ELLIPTA global net sales increased by 5% in the second quarter of 2020 compared to the second quarter of the prior year.
  • Second quarter 2020 net sales of RELVAR/BREO ELLIPTA by GSK were $303.8 million, down 3% from $313.9 million in the second quarter of 2019, with $103.3 million in net sales from the U.S. market and $200.5 million from non-U.S. markets.
  • Second quarter 2020 net sales of ANORO ELLIPTA by GSK were $172.3 million, up 5% from $163.6 million in the second quarter of 2019, with $109.8 million net sales from the U.S. market and $62.5 million from non-U.S. markets.

GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

Retrieved on: 
Wednesday, October 2, 2019
Research, Pharmaceutical, Medical devices, Science, Clinical trials, Biotechnology, Medical Supplies, FDA, Health, Drugs, Medicine, Combination drugs, Ellipta, Clinical medicine, Fluticasone furoate/vilanterol, Muscarinic antagonists, Fluticasone furoate, Umeclidinium bromide/vilanterol, Vilanterol, Chronic obstructive pulmonary disease, GlaxoSmithKline, asthma, the CAPTAIN Study, Trelegy Ellipta (FF/UMEC/VI) in the US, GSK, Innoviva

Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
  • If approved, this filing would make Trelegy Ellipta the first and only single inhaled triple therapy available for both asthma and COPD in the US.
  • Candida albicans infection of the mouth and pharynx has occurred in patients treated with fluticasone furoate, a component of Trelegy Ellipta.
  • Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA, ANORO ELLIPTA and TRELEGY ELLIPTA, which were jointly developed by Innoviva and GSK.

GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

Retrieved on: 
Wednesday, October 2, 2019
FDA, Health, Clinical trials, General Health, Pharmaceutical, Drugs, Medicine, Combination drugs, Clinical medicine, Ellipta, Chronic lower respiratory diseases, Long-acting beta-adrenoceptor agonist, Fluticasone furoate/vilanterol, Muscarinic antagonists, Umeclidinium bromide/vilanterol, Respiratory therapy, Chronic obstructive pulmonary disease, asthma, the CAPTAIN Study, Trelegy Ellipta (FF/UMEC/VI) in the US, GSK, Innoviva

Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • Trelegy Ellipta was approved in the US in September 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
  • Christopher Corsico, SVP Development, GSK said: Around 30% of asthma patients adherent to ICS/LABA combination therapy still experience symptoms.
  • If approved, this filing would make Trelegy Ellipta the first and only single inhaled triple therapy available for both asthma and COPD in the US.
  • Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA, ANORO ELLIPTA and TRELEGY ELLIPTA, which were jointly developed by Innoviva and GSK.